SCHEMBL5218508

SCHEMBL5218508

Cc1cc(Cl)ccc1-n1nc(-c2ccc(O)cc2)c(-c2ccc(O)cc2)c1-c1ccc(O)cc1

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.46
PPARA Q07869 2/20 0.46
CNR2 P34972 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5218760 0.95 CNR1 (0.43) CNR1PPARACNR2
SCHEMBL5215784 0.86 CNR1 (0.53) CNR1PPARACNR2
SCHEMBL5222191 0.85 CNR2 (0.49) CNR1PPARACNR2
SCHEMBL5217431 0.82 CNR1 (0.49) CNR1PPARACNR2
SCHEMBL5216012 0.82 CA1 (0.43)
SCHEMBL5221200 0.82 KDM4E (0.49) CNR1PPARACNR2
SCHEMBL5217969 0.81 MAPT (0.43)
SCHEMBL5214152 0.81 ESR1 (0.42) CNR1PPARACNR2
SCHEMBL5215623 0.78 KMT2A (0.44)
SCHEMBL5217216 0.77 ESR1 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39708-E1 Estrogen receptor modulators CHIRON CORPORATION (US) 2007-06-26 US disclosed
EP-1102753-B1 PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS NOVARTIS VACCINES & DIAGNOSTIC (US) 2007-02-28 EP disclosed
US-6727273-B2 THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS CHIRON CORPORATION 2004-04-27 US disclosed
US-20040077701-A1 Estrogen receptor modulators CHIRON CORPORATION (US) 2004-04-22 US disclosed
US-20040034081-A9 ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION 2004-02-19 US disclosed
US-20020111374-A1 Estrogen receptor modulators CHIRON CORPORATION 2002-08-15 US disclosed
US-6291505-B1 PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST CHIRON CORPORATION 2001-09-18 US disclosed
EP-1102753-A2 PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2001-05-30 EP disclosed
WO-2000007996-A2 PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077701-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 CNR1 160/4885PPARA 64/4885CNR2 323/4885
US-20040034081-A9 ESTROGEN RECEPTOR MODULATORS ESR1, ESR2, GPER1 CNR1 160/4885PPARA 64/4885CNR2 323/4885
US-20020111374-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 CNR1 160/4885PPARA 64/4885CNR2 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.